The optimal role of β-adrenergic receptor blockade in the perioperative period remains unclear in patients at risk for cardiovascular events. Cardiovascular complications continue to be the most common cause of perioperative morbidity and mortality, and cardioprotective properties of β-blockers are widely recognized, yet the results of the clinical trials investigating the use of different β-blockers in the perioperative period are controversial. The discrepancy might be related to differences in the design of studies, use of different agents, administration by different routes, and continuation for different time intervals. Evidently, perioperative mortality and morbidity seem to be related to heart rate, and the majority of complications are related to β-blockers’ side effects. Based on the observations from different studies, we propose an algorithm for perioperative β blockade.
POISE Study Group.Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet . 2008;371(9627):1839-1847.
2.
Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation. 2006;113(22):2662-2674.
3.
Frishman WHMultifactorial actions of beta-adrenergic-blocking drugs in ischemic heart disease: current concepts. Circulation . 1983 ;67(6 pt 2):11-18.
4.
Wallhouse TR , Taylor M., De Grado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation . 2001;103(20):2441-2446.
5.
Okafor CC, Perreault-Micale C., Hajjar RJ, et al. Chronic treatment with Carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. BMC Physiology. 2003;3:6.
6.
Nishimiya T. , Daniell HB, Webb JG, et al. Chronic treatment with propranolol enhances the synthesis of prostaglandins E2 and I2 by the aorta of spontaneously hypertensive rats. J Pharmacol Exper Ther. 1990; 253(1):207-213.
7.
Investigators.RESOLVD Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study. Circulation. 2000;101(4):378-384.
8.
Norris RM, Barnaby PF, Brown MA, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet. 1984;2(8408): 883-886.
9.
Snow PJDEffect of propranolol in myocardial infarction . Lancet. 1965;2(7412):551-553.
10.
Balcon R., Jewitt DE, Davies JPH, Oram S.A controlled trial of propranolol in acute myocardial infarction. Lancet. 1966;2(7470):917-920.
11.
Clausen J., Felsby M., Jorgensen FS, Nielsen BL, Roin J., Strange B.Absence of prophylactic effect of propranolol in myocardial infarction . Lancet. 1966;2(7470): 920-924.
12.
β-Blocker Heart Attack Trial Research Group (B-HAT).A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results. JAMA . 1982;247(12):1707-1714.
13.
The MIAMI Trial Research Group.Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J.1985;6(3): 199-226.
14.
ISIS-1 (First International Study of Infarct Survival) Collaborative Group.Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1 . Lancet. 1986;2(8498):57-66.
15.
Roberts R., Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83(2):422-437.
16.
Antman EM, Hand M., Armstrong PW, et al. 2007Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction). Circulation. 2008;117(6):296-329.
17.
Anderson JL , Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation. 2007;116(7):e148-e304.
18.
Fraker TD Jr , Fihn SD writing on behalf of the 2002 Chronic Stable Angina Writing Committee. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina . Circulation. 2007;116(23):2762-2772.
19.
Smith SC, Allen J., Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113(19):2363-2372.
20.
Braunwald E. , Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol.2002;40(7):1366-1374.
21.
Chen ZM, Pan HC, Chen YP, et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group.Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005; 366(9497):1622-1632.
22.
Packer M.Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists. J Cardiovasc Pharmacol. 1989;14(suppl 5):38-43.
23.
Metra M., Nardi M., Giubbini R., Dei CLEffects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol . 1994;24(7): 1678-1687.
24.
Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MRCarvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol . 1995;25(6):1225-1231.
25.
Krum H., Sackner-Bernstein JD, Goldsmith RL, et al. Double blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92(6):1499-1506.
26.
Packer M., Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial: Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996;94(11):2793-2799.
27.
Cibis IIInvestigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomized trial. Lancet. 1999;353(9146):9-13.
28.
Goldstein S. , Hjalmarson A.The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF trial. Clin Cardiol. 1999;22(suppl 5):30-35.
29.
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol.2005 ;46(6):1-82.
30.
Eichhorn E. , Domanski M., Krause-Steinrauf H., Anderson J.A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659-1667.
31.
Poole-Wilson PA, Swedberg K., Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377): 7-13.
32.
Fonarow GC, Abraham WT, Albert NM, et al; OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008;52(3):190-199.
33.
WHO/ISH Writing Group.2003World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-1992.
34.
European Society of Hypertension Guidelines Committee.2003European Society of Hyertension-European Society of Cardiology guidelines for the management of arterial hypertension . J Hypertens. 2003;21(6):1011-1053.
35.
JNC VI. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med.1997;157(21): 2413-2446.
36.
Chobanian AV , Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC report. Hypertension. 2003 ;42(6):1206-1252.
37.
MRC Working Party.Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J.1992;304(6824):405-412.
38.
Messerli FH , Grossman F., Goldbourt U.Are beta-blockers efficacious as first-line therapy for hypertension in elderly? A systematic review. JAMA. 1998;279(23): 1903-1907.
39.
Lindholm LH , Persson M., Alaupovic P., et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21(8):1563-1574.
40.
Pischon T., Sharma AMUse of beta-blockers in obesity hypertension: potential role of weight gain . Obes Rev. 2001;2(4):275-280.
41.
Jacob S., Rett K., Henriksen EJAntihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens. 1998;11(10): 1258-1265.
42.
Kveiborg B. , Christiansen B., Major-Petersen A., Torp-Pedersen C.Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol . Am J Cardiovasc Drugs. 2006;6(4):209-217.
43.
Kaiser T., Heise T., Nosek L., Eckers U., Sawicki PTInfluence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens . 2006;24(7):1397-1403.
44.
The ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
45.
Coleman AJ, Jordan C.Cardiovascular responses to anaesthesia: influence of beta adrenoreceptor blockade with metoprolol. Anaesthesia. 1980 ;35(10):972-978.
46.
Selzman CH, Miller SA, Zimmerman MA, Harken AHThe case for beta-adrenergic blockade as prophylaxis against perioperative cardiovascular morbidity and mortality. Arch Surg. 2001;136(3):286-290.
47.
Cucchiara RF , Benefiel DJ, Matteo RS, DeWood M., Albin MSEvaluation of esmolol in controlling increases in heart rate and blood pressure during endotracheal intubation in patients undergoing carotid endarterectomy. Anesthesiology. 1986;65(5):528-531.
48.
Jakobsen CJ , Grabe N., Christensen B.Metoprolol decreases the amount of halothane required to induce hypotension during general anaesthesia. Br J Anaesth. 1986;58(3):261-266.
49.
Liu PL, Gatt S., Gugino LD, Mallampati SR, Covino BGEsmolol for control of increases in heart rate and blood pressure during tracheal intubation after thiopentone and succinylcholine. Can Anaesth Soc J. 1986;33(5): 556-562.
50.
Magnusson J. , Thulin T., Werner O., Jarhult J., Thomson D.Haemodynamic effects of pretreatment with metoprolol in hypertensive patients undergoing surgery. Br J Anaesth. 1986;58(3):251-260.
51.
Gibson BE, Black S., Maass L., Cucchiara RFEsmolol for the control of hypertension after neurologic surgery. Clin Pharmacol Ther. 1988;44(6):650-653.
52.
Stone JG, Foex P., Sear JW, Johnson LL, Khambatta HJ, Triner L.Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent. Anesthesiology . 1988;68(4): 495-500.
53.
Mackenzie JW , Bird J.Timolol: a non-sedative anxiolytic premedicant for day cases. BMJ. 1989;298(6670): 363-364.
54.
Inada E., Cullen DJ, Nemeskal AR, Teplick R.Effect of labetalol or lidocaine on the hemodynamic response to intubation: a controlled randomized double-blind study. J Clin Anesth . 1989;1(3):207-213.
55.
Leslie JB, Kalayjian RW, McLoughlin TM, Plachetka JRAttenuation of the hemodynamic responses to endotracheal intubation with preinduction intravenous labetalol. J Clin Anesth. 1989 ;1(3):194-200.
56.
Jakobsen CJ , Blom L., Brondbjerg M., Lenler-Petersen P.Effect of metoprolol and diazepam on pre-operative anxiety. Anaesthesia . 1990;45(1):40-43.
57.
Miller D., Martineau R., Hull K., Hill J.Bolus administration of esmolol for controlling the hemodynamic response to laryngoscopy and intubation: efficacy and effects on myocardial performance . J Cardiothorac Anesth. 1990;4(suppl 2):31-36.
58.
Miller DR, Martineau RJ, Wynands JE, Hill J.Bolus administration of esmolol for controlling the haemodynamic response to tracheal intubation: the Canadian multicentre trial. Can J Anaesth. 1991;38(7):849-858.
59.
Davies MJ, Dysart RH, Silbert BS, Scott DA, Cook RJPrevention of tachycardia with atenolol pretreatment for carotid endarterectomy under cervical plexus blockade. Anaesth Intensive Care. 1992;20(2):161-164.
60.
Jakobsen CJ , Bille S., Ahlburg P., Rybro L., Pedersen KD, Rasmussen B.Preoperative metoprolol improves cardiovascular stability and reduces oxygen consumption after thoracotomy. Acta Anaesthesiol. Scand.1997;41(10): 1324-1330.
61.
Mangano DT, Layug EL, Wallace A., Tateo I.Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery: Multicenter Study of Perioperative Ischemia Research Group . N Engl J Med. 1996; 335(23):1713-1720.
62.
Raby KE, Brull SJ, Timimi F.The effect of heart rate control on myocardial ischemia among high risk patients after vascular surgery. Anesth Analg. 1999 ;88(3): 477-482.
63.
Urban MK, Markowitz SM, Gordon MA, Urquhart BL, Kligfield P.Postoperative prophylactic administration of beta-adrenergic blockers in patients at risk for myocardial ischemia. Anesth Analg . 2000;90(6):1257-1261.
64.
Poldermans D., Boersma E., Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;341(24):1789-1794.
65.
Wijeysundera DN, Beattie WSCalcium channel blockers for reducing cardiac morbidity after noncardiac surgery: a meta-analysis. Anesth Analg. 2003;97(3): 634-641.
66.
Lindenauer PK, Pekow P., Wang K., Mamidi DK, Gutierrez B., Benjamin EMPerioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med.2005;353(4):349-361.
67.
Auerbach AD , Goldman L.Beta-blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA. 2002;287(11):1435-1444.
68.
Redelmeier D., Scales D., Kopp A.Beta-blockers for elective surgery in elderly patients: population based, retrospective cohort study . BMJ . 2005;331(7522):932-934.
69.
Daumerie G. , Fleisher LAPerioperative beta-blocker and statin therapy . Curr Opin Anaesthesiol.2008;21(1):60-65.
70.
Giles JW, Sear JW, Foex P.Effect of chronic beta-blockade on perioperative outcome in patients undergoing noncardiac surgery: an analysis of observational and case control studies . Anaesthesia. 2004;59(11): 574-583.
71.
Shammash JB , Trost JC, Gold JM, Berlin JA, Golden MA, Kimmel SEPerioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J. 2001;141(1):148-153.
72.
Hoeks SE, Scholte OpReimer WJ, van Urk H., et al. Increase of 1-year mortality after perioperative β-blocker withdrawal in endovascular and vascular surgery patients. Eur J Vasc Endovasc Surg.2007;33(1):13-19.
73.
Rahman M., Douglas JG, Wright JT Jr.Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am . 1997;26(1):125-144.
74.
Yancy CW, Fowler MB, Colucci WS, et al; US Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure . N Engl J Med. 2001;344(18): 1358-1365.
75.
Lanfear DE, Jones PG, Marsh S., Cresci S., McLeod HL, Spertus JABeta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA . 2005;294(12): 1526-1533.
76.
Liggett SB, Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure . Proc Natl Acad Sci U S A.2006;103(30):11288-11293.
77.
White M., Carson P., Anand IS, et al. Abstract 901: effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 arg/gly receptor polymorphism . Circulation. 2007;116:II_176.
78.
Schwarz ER, Gupta R., Diep TP, et al. Carvedilol improves myocardial contractility compared with metoprolol in patients with chronic hibernating myocardium after revascularization. J Cardiovasc Pharmacol Ther. 2005;10(3):181-190.
